Takeda Pharmaceutical Company Limited
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Takeda Pharmaceutical Company Limited operates globally, dedicated to the research, development, production, and commercialization of innovative biopharmaceutical treatments. The company focuses its scientific efforts and delivers therapies across several key areas: gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Its portfolio includes prominent brands such as Entyvio for inflammatory bowel diseases, Vyvanse for ADHD, and Takhzyro for rare genetic conditions, alongside various other products for oncology and plasma-derived needs. With operations spanning approximately 80 countries and regions worldwide, Takeda maintains a significant presence across Japan, the United States, Europe, Latin America, Africa, the Middle East, and the Asia Pacific. The company actively engages in strategic alliances and licensing agreements to advance its pipeline and expand its market reach. Recent collaborations include a notable $11.4 billion deal with China's Innovent Biologics in October 2025 to accelerate immuno-oncology and antibody-drug conjugate cancer therapies. Additionally, Takeda expanded its partnership with Beacon Biosignals in November 2025 to further narcolepsy diagnosis and neurobiomarker discovery. The company also received FDA approval for Eohilia, an oral treatment for allergic inflammation of the esophagus, in February 2024. Founded in 1781, Takeda is headquartered in Tokyo, Japan, and remains a leading global biopharmaceutical firm driven by a patient-centric approach and commitment to sustainable healthcare solutions. It consistently invests substantially in research and development, with a robust late-stage pipeline aimed at delivering life-transforming medicines.
Takeda Pharmaceutical Co Ltd (TAK) Shares Fall 4.8% -- GF Value Says Still Overvalued
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds
Takeda's Rich Pipeline Optionality Is Worth A 'Buy'
Takeda Pharmaceutical Q4 Earnings Call Highlights
Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
Takeda's immune disease drug meets main goal of mid-to-late stage trial
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
Assetmark Inc. Buys 33,902 Shares of Takeda Pharmaceutical Co. $TAK
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
My Top 4 Pharma Picks Under Rising Geopolitical Risk
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why
Takeda Pharmaceutical Co. $TAK Shares Acquired by JPMorgan Chase & Co.
Takeda Pharmaceutical Company Limited (TAK) Discusses Zasocitinib Phase III Psoriasis Data and Commercial Strategy Transcript
Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
TrumpRx lists many medicines at prices higher than paid in UK